Tinavi Medical TechnologiesLtd Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jin Xu

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	0.07%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	5.7yrs

Son yönetim güncellemeleri

Recent updates

What Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) 60% Share Price Gain Is Not Telling You

Oct 09

Is Tinavi Medical TechnologiesLtd (SHSE:688277) A Risky Investment?

Jun 14

More Unpleasant Surprises Could Be In Store For Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) Shares After Tumbling 26%

Apr 21

There's Reason For Concern Over Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) Massive 25% Price Jump

Mar 06

Health Check: How Prudently Does Tinavi Medical TechnologiesLtd (SHSE:688277) Use Debt?

Feb 27

CEO

Jin Xu (50 yo)

no data

Görev süresi

CN¥1,171,000

Tazminat

Mr. Jin Xu serves as the General Manager and Director of TINAVI Medical Technologies Co., Ltd.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jin Xu	GM & Director	no data	CN¥1.17m	0.071% CN¥ 3.1m
Changjiu Dai	Independent Director	5.5yrs	CN¥100.00k	Veri yok
Dequan Zhu	Director	14yrs	Veri yok	Veri yok
Zhi Xiao	Director	5.9yrs	Veri yok	Veri yok
Yan Li	Independent Director	5.5yrs	CN¥100.00k	Veri yok
Songgen Zhang	Chairman	14yrs	CN¥1.22m	16.84% CN¥ 733.9m
Binbin Wang	Director	8.8yrs	CN¥976.00k	0.024% CN¥ 1.1m
Guangzhi Wang	Independent Director	5.5yrs	CN¥100.00k	Veri yok
Zhaoqi Zhu	Supervisor	4.1yrs	Veri yok	Veri yok

5.7yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 688277 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.7 yıldır).

Tinavi Medical TechnologiesLtd Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Tinavi Medical Technologies Co.,Ltd., Annual General Meeting, Jun 27, 2024

Less than half of directors are independent

Recent updates

What Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) 60% Share Price Gain Is Not Telling You

New minor risk - Share price stability

Tinavi Medical Technologies Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.085 loss per share (vs CN¥0.093 loss in 2Q 2023)

Tinavi Medical Technologies Co.,Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Is Tinavi Medical TechnologiesLtd (SHSE:688277) A Risky Investment?

Tinavi Medical Technologies Co.,Ltd., Annual General Meeting, Jun 27, 2024

Full year 2023 earnings released: CN¥0.35 loss per share (vs CN¥0.26 loss in FY 2022)

More Unpleasant Surprises Could Be In Store For Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) Shares After Tumbling 26%

Tinavi Medical Technologies Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

There's Reason For Concern Over Tinavi Medical Technologies Co.,Ltd.'s (SHSE:688277) Massive 25% Price Jump

Full year 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.26 loss in FY 2022)

Health Check: How Prudently Does Tinavi Medical TechnologiesLtd (SHSE:688277) Use Debt?

Third quarter 2023 earnings released: CN¥0.082 loss per share (vs CN¥0.088 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.093 loss per share (vs CN¥0.039 loss in 2Q 2022)

TINAVI Medical Technologies Co., Ltd. to Report Q2, 2023 Results on Aug 23, 2023

Full year 2022 earnings released: CN¥0.26 loss per share (vs CN¥0.19 loss in FY 2021)

Full year 2022 earnings released: CN¥0.27 loss per share (vs CN¥0.19 loss in FY 2021)

Beijing Huilin Oriental Technology Partnership Enterprise (Limited Partnership) and Wang Binbin entered into an agreement to acquire 12% stake in Beijing Shuimu Dongfang Medical Robotics Technology Innovation Center Co., Ltd. from TINAVI Medical Technologies Co., Ltd. (SHSE:688277).

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.088 loss per share (vs CN¥0.06 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.039 loss per share (vs CN¥0.031 loss in 2Q 2021)

First quarter 2022 earnings released: CN¥0.07 loss per share (vs CN¥0.06 loss in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: CN¥0.06 loss per share (vs CN¥0.04 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.031 loss per share (vs CN¥0.049 loss in 2Q 2020)

TINAVI Medical Technologies Co., Ltd. announced that it expects to receive CNY 1.34 billion in funding

First quarter 2021 earnings released: CN¥0.06 loss per share (vs CN¥0.04 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.14 loss per share (vs CN¥0.08 loss in FY 2019)

New 90-day low: CN¥34.82

New 90-day low: CN¥45.92

New 90-day low: CN¥55.62

TINAVI Medical Technologies Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş